Glomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa

Abstract

Background

The aim of this study was to investigate long-term renal function in HIV-infected adults initiating antiretroviral therapy (ART) with a CD4⁺ T-cell count <200 cells/mm³ in Africa.

Methods

This was an observational analysis within the DART trial randomizing 3,316 adults to routine laboratory and clinical monitoring (LCM) or clinically driven monitoring (CDM). Serum creatinine was measured pre-ART (all ≤360 μmol/l), at weeks 4 and 12, then every 12 weeks for 4-5 years; estimated glomerular filtration rate (eGFR) was determined using the Cockcroft-Gault formula. We analysed eGFR changes, and cumulative incidences of eGFR<30 ml/min/1.73 m² and chronic kidney disease (CKD; <60 ml/min/1.73 m² or 25% decrease if <60 ml/min/1.73 m² pre-ART; confirmed >3 months).

Results

At ART initiation, median CD4⁺ T-cell count was 86 cells/mm³; 1,492 (45%) participants had mild (60–<90 ml/min/1.73 m²), 237 (7%) moderate (30–<60 ml/min/1.73 m²) and 7 (0.2%) severe (15–<30 ml/min/1.73 m²) decreases in eGFR. First-line ART was zidovudine/lamivudine plus tenofovir (74%), abacavir (9%) or nevirapine (17%). By 4 years, cumulative incidence of eGFR<30 ml/min/1.73 m² was 2.8% (n=90) and CKD was 5.0% (n=162). Adjusted eGFR increases to 4 years were 1, 9 and 6 ml/min/1.73 m² with tenofovir, abacavir and nevirapine, respectively (P<0.001), and 4 and 2 ml/min/1.73 m² for LCM and CDM, respectively (P=0.005; 2 and 3 ml/min/1.73 m² to 5 years; P=0.81).

Conclusions

On all regimens and monitoring strategies, severe eGFR impairment was infrequent; differences in eGFR changes were small, suggesting that first-line ART, including tenofovir, can be given safely without routine renal function monitoring.

References

Röling

, Schmid

, Fischereder

, Draenert

, Goebel

F.D.

HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42: 1488–1495.

Post

F.A.

, Holt

S.G.

Recent developments in HIV and the kidney. Curr Opin Infect Dis 2009; 22: 43–48.

Wyatt

C.M.

HIV and the kidney: a spotlight on racial disparities. J Infect Dis 2008; 197: 1490–1492.

Lucas

G.M.

, Lau

, Atta

M.G.

, Fine

D.M.

, Keruly

, Moore

R.D.

Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008; 197: 1548–1557.

Wools-Kaloustian

K.K.

, Gupta

S.K.

Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tell. Kidney Int 2008; 74: 845–847.

Andia

, Pepper

, Matheison

Prevalence of renal disease in patients attending the HIV/AIDS clinic, at Mbarara University Teaching Hospital. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24–27 July 2005, Rio de Janeiro, Brazil. Abstract TuPe 15.3C02.

Gerntholtz

T.E.

, Goetsch

S.J.

, Katz

HIV-related nephropathy: a South African perspective. Kidney Int 2006; 69: 1885–1891.

Han

T.M.

, Naicker

, Ramdial

P.K.

, Assounga

A.G.

A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006; 69: 2243–2250.

Olson

, Thomas

, Allheimen

, Balkan

, Szumilin

, Humblet

Impaired renal function of patients initiating HAART in two developing countries. 13th Conference on Retroviruses and Opportunistic Infections. 5–8 February 2006, Denver, CO, USA. Abstract 771.

10.

Wools-Kaloustian

, Gupta

S.K.

, Muloma

Renal disease in an antiretroviral-naive HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant 2007; 22: 2208–2212.

11.

Emem

C.P.

, Arogundade

, Sanusi

, Adelusola

, Wokoma

, Akinsola

Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 2008; 23: 741–746.

12.

Mulenga

L.B.

, Kruse

, Lakhi

Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008; 22: 1821–1827.

13.

Wools-Kaloustian

, Ong'or

W.O.

, Wafula

The relationships between renal dysfunction and clinical outcomes in HIV-infected Kenyans not requiring immediate ART. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February, Montreal, QC, Canada. Abstract 741.

14.

Peters

P.J.

, Moore

D.M.

, Mermin

Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 2008; 74: 925–929.

15.

Reid

, Stöhr

, Walker

A.S.

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46: 1271–1281.

16.

DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123–131.

17.

Karras

, Lafaurie

, Furco

Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070–1073.

18.

Rifkin

B.S.

, Perazella

M.A.

Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004; 117: 282–284.

19.

Peyrière

, Reynes

, Rouanet

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269–273.

20.

Zimmermann

A.E.

, Pizzoferrato

, Bedford

, Morris

, Hoffman

, Braden

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283–290.

21.

Goicoechea

, Liu

, Best

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102–108.

22.

Jülg

B.D.

, Bogner

J.R.

, Crispin

, Goebel

F.D.

Progression of renal impairment under therapy with tenofovir. AIDS 2005; 19: 1332–1333.

23.

Mocroft

, Kirk

, Gatell

Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21: 1119–1127.

24.

Gallant

J.E.

, Winston

J.A.

, DeJesus

The 3-year renal safety of a tenofovir disoproxil fumarate vs a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008; 22: 2155–2163.

25.

Stöhr

, Walker

A.S.

, Munderi

Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft–Gault and Modification of Diet in Renal Disease formulae. Antivir Ther 2008; 13: 761–770.

26.

World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV-1 infection and disease. Wkly Epidemiol Rec 1990; 65: 221–224.

27.

DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS 2008; 22: 237–247.

28.

World Health Organization. Scaling up antiviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization 2002.

29.

DART Trial Team. Twenty-four-week safety and tolerability of nevirapine vs abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 2008; 13: 6–16.

30.

Cockcroft

D.W.

, Gault

M.H.

Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

31.

Levey

A.S.

, Coresh

, Balk

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–147.

32.

Mocroft

, Kirk

, Reiss

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667–1678.

33.

Levey

A.S.

, Coresh

, Greene

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–254.

34.

Levey

A.S.

, Stevens

L.A.

, Schmid

C.H.

A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.

35.

Fine

J.P.

, Gray

R.J.

A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

36.

Gazzard

B.G.

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608.

37.

Hammer

S.M.

, Eron

J.J.

Jr. , Reiss

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel. JAMA 2008; 300: 555–570.

38.

World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization 2009.

39.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization 2010.

40.

Mwango

, Giganti

, Mulenga

First-line tenofovir ART: Zambia. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February, Montreal, QC, Canada; 2009.

41.

European Medicines Agency (EMEA). Viread - product information 2009. (Updated 26 April 2011. Accessed 15 June 2011.) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000419/WC500051737.pdf.

42.

Vrouenraets

, Garcia

E.F.

, Wit

A comparison between different GFR-estimations and [125I]-iothalamate, the gold standard for GFR-measurement, in HIV-infected patients on HAART. 15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract 977b.

43.

Winston

J.A.

Estimating glomerular filtration rate in patients with HIV infection. Semin Nephrol 2008; 28: 576–580.

44.

Barraclough

, Er

, Ng

, Harris

, Montaner

, Levin

A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract 2009; 111: c39–c48.

45.

Gupta

S.K.

, Eustace

J.A.

, Winston

J.A.

Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559–1585.

46.

Froissart

, Rossert

, Jacquot

, Paillard

, Houillier

Predictive performance of the modification of diet in renal disease and Cockcroft–Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16: 763–773.

47.

van Deventer

H.E.

, George

J.A.

, Paiker

J.E.

, Becker

P.J.

, Katz

I.J.

Estimating glomerular filtration rate in black South Africans by use of the modification of diet in renal disease and Cockcroft–Gault equations. Clin Chem 2008; 54: 1197–1202.

48.

Eriksen

B.O.

, Ingebretsen

O.C.

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression. Kidney Int 2007; 72: 1242–1248.

49.

Regulatory Compliance Center. Division of AIDS table for grading severity of adult adverse experiences. Bethesda: National Institute of Allergy and Infectious Diseases 1992.